Pharmacologic characteristics of prulifloxacin

Pulmonary Pharmacology and Therapeutics

Volumn 19, Issue SUPPL. 1, 2006, Pages 20-29

  Matera, Maria Gabriella ^a,b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b NONE   (Italy)

Author keywords

Antimicrobial activity; Pharmacodynamics; Pharmacokinetics; Prulifloxacin

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTACID AGENT; CARBON 14; CIMETIDINE; CIPROFLOXACIN; DRUG METABOLITE; ENOXACIN; FENBUFEN; FLEROXACIN; GATIFLOXACIN; IRON; LEVOFLOXACIN; LOMEFLOXACIN; MOXIFLOXACIN; NORFLOXACIN; OFLOXACIN; PEFLOXACIN; PROBENECID; PRODRUG; PRULIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; THEOPHYLLINE; TOSUFLOXACIN; ULIFLOXACIN; UNCLASSIFIED DRUG;

CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC BRONCHITIS; CLINICAL TRIAL; CONVULSION; DISEASE EXACERBATION; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INHIBITION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG URINE LEVEL; ESCHERICHIA COLI; FOOD DRUG INTERACTION; HAEMOPHILUS; HUMAN; KLEBSIELLA; LIVER TOXICITY; MORGANELLA; NONHUMAN; PHOTOTOXICITY; PRIORITY JOURNAL; PROTEUS; PROVIDENCIA; PSEUDOMONAS AERUGINOSA; QT PROLONGATION; RESPIRATORY TRACT INFECTION; REVIEW; SINGLE DRUG DOSE; URINARY TRACT INFECTION;

ANTI-INFECTIVE AGENTS; BACTERIA; DIOXOLANES; FLUOROQUINOLONES; HUMANS; PIPERAZINES; QUINOLONES;

EID: 30344478219     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2005.09.009     Document Type: Review

References (54)

1. H. Takahashi, I. Hayakawa, and T. Akimoto The history of the development and changes of quinolone antibacterial agents Yakushigaku Zasshi 38 2003 161 179
2. Hooper DC, Wolfson JS, editors. Quinolone antimicrobial agents, 2nd ed, vol. 3. Washington, DC: American Society for Microbiology; 1993.
3. L.J.V. Piddock New quinolones and Gram-positive bacteria Antimicrob Agents Chemother 38 1994 163 169
4. S.J. Keam, and C.M. Perry Prulifloxacin Drugs 64 2004 2221 2234
5. M. Tani, K. Maebashi, M. Araake, and H. Watabe Inhibitory activity of NM394, the active form of prodrug prulifloxacin against type II topoisomerase from Pseudomonas aeruginosa Jpn J Antibiot 55 2002 882 885
6. Y. Yoshida, and S. Mitsuhashi Antibacterial activity of NM394, the active form of prodrug NM441, a new quinolone Antimicrob Agents Chemother 37 1993 793 800
7. Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, editors. Manual of clinical microbiology, 7th ed, vol. 5. Washington, DC: American Society for Microbiology; 1999.
8. A.L. Koch Growth measurement P. Gerhardt R.G.E. Murray W.A. Wood N.R. Krieg Methods for general and molecular bacteriology 1994 American Society for Microbiology Washington, DC 248 277
9. National Committee for Clinical Laboratory Standards. Methods for determining bactericidal activity of antimicrobial agents. Tentative guideline M26-T. National Committee for Clinical Laboratory Standards, Villanova, PA, 1992.
10. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 5th ed. Approved standard M7-A5. National Committee for Clinical Laboratory Standards, Wayne, PA, 2000.
11. M. Ozaki, M. Matsuda, Y. Tomii, K. Kimura, K. Kazuno, M. Kitano, M. Kise, K. Shibata, M. Otsuki, and T. Nishino In vitro antibacterial activity of a new quinolone, NM394 Antimicrob Agents Chemother 35 1991 2490 2495
12. M. Araake, T. Hara, H. Watabe, and T. Nishino In vitro antibacterial activity of prulifloxacin, a new oral fluoroquinolone Jpn J Antibiot 55 2002 778 790
13. M. Inoue, A. Kuga, S. Kaieda, M. Hosaka, H. Kitasato, Y. Sato, R. Okamoto, T. Eda, K. Hoshino, and I. Seto In vitro antibacterial activity of prulifloxacin, a new oral quinolone, and comparative susceptibility rate at clinical breakpoint MIC Jpn J Antibiot 53 2000 593 608
14. G. Prats, C. Roig, E. Miro, F. Navarro, and B. Mirelis In vitro activity of the active metabolite of prulifloxacin (PUFX) compared with six other fluoroquinolones Eur J Clin Microbiol Infect Dis 21 2002 328 334
15. M.P. Montanari, M. Mingoia, and P.E. Varaldo In vitro antibacterial activities of AF 3013, the active metabolite of prulifloxacin, against nosocomial and community Italian isolates Antimicrob Agents Chemother 38 2001 799 807
16. A. Vasquez, T. Jakobsson, S. Ahrne, U. Forsum, and G. Molin Vaginal Lactobacillus flora of healthy Swedish women J Clin Microbiol 40 2002 2746 2749
17. M.V. Pirotta, J.M. Gunn, and P. Chondros "Not trash again!". Women experience of post-antibiotic vulvovaginitis MJA 179 2003 43 46
18. Tempera A. In vitro antibacterial activity of prulifloxacin against clinically isolated vaginal lactobacillus strains. Rome: Angelini - ACRAF S.p.A., 2005 (data on file).
19. G.A. Pankuch, M.R. Jacobs, and P.C. Appelbaum Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology Antimicrob Agents Chemother 38 1994 2065 2072
20. L.J. Piddock Mechanism of quinolone uptake into bacterial cells J Antimicrob Chemother 27 1991 399 403
21. S.L. Nielsen, N. Obel, M. Storgaard, and P.L. Andersen The effect of quinolones on the intracellular killing of Staphylococcus aureus in neutrophil granulocytes J Antimicrob Chemother 39 1997 617 622
22. M. Shimizu, M. Tabata, T. Hara, M. Araake, H. Watabe, and T. Nishino In vitro short-term bactericidal activity and accumulation of NM394, the active metabolite of prulifloxacin, for Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa: comparison with ciprofloxacin, levofloxacin, and gatifloxacin Jpn J Antibiot 55 2002 791 799
23. Broccali GP, Visconti M. Evaluation of the postantibiotic effect of AF 3013 in comparison to ciprofloxacin. Rome: Angelini - ACRAF S.p.A., 1995 (data on file).
24. P.H. Edelstein, M.A. Edelstein, J. Ren, R. Polzer, and R.P. Gladue Activity of trovafloxacin (CP-99,219) against Legionella isolates: in vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumonia Antimicrob Agents Chemother 40 1996 314 349
25. E. Cantón, T. Jiménez, J. Pemán, M.S. Ramón, and M. Gobernado Intraphagocytic bioactivity of lomefloxacin against Pseudomonas aeruginosa J Antimicrob Chemother 32 1993 279 284
26. A. Pascual, I. García, S. Ballesta, and E.J. Perea Uptake and intracellular activity of trovafloxacin in human phagocytes and tissue-cultured epithelial cells Antimicrob Agents Chemother 41 1997 274 277
27. M.B. Carlier, B. Scorneaux, A. Zenebergh, J.F. Desnottes, and P.M. Tulkens Cellular uptake, localization and activity of fluoroquinolones in uninfected and infected macrophages J Antimicrob Chemother 46 2000 241 247
28. M. Ozaki, K. Komori, M. Matsuda, R. Yamaguchi, T. Honmura, Y. Tomii, I. Nishimura, and T. Nishino Uptake and intracellular activity' of NM394, a new quinolone, in human polymorphonuclear leukocytes Antimicrob Agents Chemother 40 1996 739 742
29. V. Tullio, A.M. Cuffini, A. Bonino, A.I. Palarchio, J. Roana, N. Mandras, V. Rossi, and N.A. Carlone Influence of a new fluoroquinolone, AF3013 (the active metabolite of prulifloxacin), on macrophage functions against Klebsiella pneumoniae: an in vitro comparison with prulifloxacin J Antimicrob Chemother 46 2000 241 247
30. V. Tullio, A.M. Cuffini, A. Bonino, A. lanni Palarchio, V. Rossi, and N.A. Carlone Cellular uptake and intraphagocytic activity of the new fluoroquinolone AF3013 against Klebsiella pneumoniae Drugs Exp Clin Res 25 1999 1 11
31. G. Reato, A.M. Cuffini, V. Tullio, N. Mandras, J. Roana, G. Banche, R. Foa, and N.A. Carlone Immunomodulating effect of antimicrobial agents on cytokine production by human polymorphonuclear neutrophils Int J Antimicrob Agents 23 2004 150 154
32. D.C. Hooper New uses for new and old quinolones and the challenge of resistance Clin Infect Dis 30 2000 243 254
33. M. Ozaki, M. Matsuda, Y. Tomii, K. Kimura, J. Segawa, M. Kitano, M. Kise, K. Shibata, M. Otsuki, and T. Nishino In vivo evaluation of NM441, a new thiazeto-quinoline derivative Antimicrob Agents Chemother 35 1991 2496 2499
34. M. Ozaki, Y. Tomii, M. Matsuda, J. Segawa, M. Kitano, M. Kise, and T. Nishino In vivo antibacterial activity of a prodrug of NM394, a thiazetoquinoline carboxylic acid derivative Chemotherapy 44 1998 21 30
35. Y. Tomii, M. Ozaki, M. Matsuda, T. Honmura, I. Nishimura, R. Yamaguchi, T. Adachi, Y. Okawa, and T. Nishino Therapeutic effect of the quinolone prodrug prulifloxacin against experimental urinary tract infections in mice Arzneimittelforschung 46 1996 1169 1173
36. K. Tougou, A. Nakamura, S. Watanabe, Y. Okuyama, and A. Morino Paraoxonase has a major role in the hydrolysis of prulifloxacin (NM441), a prodrug of a new antibacterial agent Drug Metab Dispos 26 1998 355 359
37. Y. Okuyama, K. Momota, and A. Morino Pharmacokinetics of prulifloxacin. 1st communication: absorption, distribution and excretion in rats, dogs and monkeys after a single administration Arzneimittelforschung 47 1997 276 278
38. M. Nakashima, T. Uematsu, K. Kosuge, Y. Okuyama, A. Morino, M. Ozaki, and Y. Takebe Pharmacokinetics and safety of NM441, a new quinolone, in healthy male volunteers J Clin Pharmacol 34 1994 930 937
39. H. Tanimura, K. Ishimoto, K. Murakami, K. Uchiyama, and S. Iwakura Penetration of NM441, a new quinolone, into human bile and gallbladder tissue Drugs 49 1995 337 340
40. H. Mikamo, K. Kawazoe, K. Izumi, K. Ito, and T. Tamaya NM441: penetration into gynaecological tissues and in vitro activity against clinical isolates from obstetric and gynaecological patients Drugs 49 1995 326 330
41. Y. Okuyama, and A. Morino Pharmacokinetics of prulifloxacin. 3rd communication: metabolism in rats, dogs and monkeys Arzneimittelforschung 47 1997 293 298
42. R. Picollo, N. Brion, V. Gualano, L. Millerioux, M. Marchetti, M.T. Rosignoli, and P. Dionisio Pharmacokinetics and tolerability of prulifloxacin after single oral administration Arzneimittelforschung 53 2003 201 205
43. Y. Okuyama, K. Momota, and A. Morino Pharmacokinetics of prulifloxacin. 2nd communication: pharmacokinetics and effect on hepatic drug-metabolizing enzyme activities after repeated administration and transfer into fetus and milk after a single administration in rats Arzneimittelforschung 47 1997 285 292
44. H. Lode Evidence of different profiles of side effects and drug-drug interactions among the quinolones - the pharmacokinetic standpoint Chemotherapy 47 2001 24 31
45. C. Fattore, G. Cipolla, G. Gatti, A. Bartoli, G. Orticelli, R. Picollo, L. Millerioux, G.B. Ciottoli, and E. Perucca Pharmacokinetic interactions between theophylline and prulifloxacin in healthy volunteers Clin Drug Invest 16 1998 387 392
46. R. Davis, A. Markham, and J.A. Balfour Ciprofloxacin An updated review of its pharmacology, therapeutic efficacy and tolerability. Drugs 51 1996 1019 1674
47. S. Oda, M. Ide, K. Tamura, M. Nagatani, Y. Shindo, K. Iwakura, and N. Sumi A 4-week oral toxicity study of prulifloxacin (NM441) in dogs followed by a 4-week recovery test J Toxicol Sci 21 1996 71 88
48. S. Ishibashi, M. Nakazawa, T. Tawaratani, H. Uchimoto, M. Yoshida, K. Iwakura, N. Sumi, and Y. Shindo A 13-week oral toxicity study of prulifloxacin (NM441) in rats followed by a 5-week recovery test J Toxicol Sci 21 1996 89 111
49. T. Morinaga, S. Fujii, S. Furukawa, M. Kikumori, K. Yasuhira, Y. Shindo, M. Watanabe, and N. Sumi Reproductive and developmental toxicity studies of prulifloxacin (NM441)(3) - a teratogenicity study in rabbits by oral administration J Toxicol Sci 21 1996 207 217
50. K. Kura, H. Fukui, T. Fukui, M. Okamoto, K. Tajima, C. Kurosaka, S. Hayashi, H. Fujisawa, K. Inoue, Y. Ukai, F. Ueda, Y. Yoshikuni, and K. Kimura General pharmacological studies of NM441. (1). Effects on central and peripheral nervous systems, gastrointestinal tract and smooth muscle Jpn J Chemother 44 1996 113 128
51. K. Kura, A. Ochi, M. Tanaka, M. Okamoto, S. Hayashi, T. Ozaki, M. Takebe, N. Matsuo, K. Inoue, F. Ueda, Y. Yoshikuni, and K. Kimura General pharmacological studies of NM441. (2). Effects on respiratory and cardiovascular systems, renal function and others Jpn J Chemother 44 1996 129 146
52. P. Lacroix, W.J. Crumb, L. Durando, and G.B. Ciottoli Prulifloxacin: in vitro (ERG) and in vivo (conscious dog) assessment of cardiac risk Eur J Pharmacol 477 2003 69 72
53. M. Akita, Y. Shibazaki, M. Izumi, K. Hiratsuka, T. Sakai, T. Kurosawa, and Y. Shindo Comparative assessment of prulifloxacin, sparfloxacin, gatifloxacin and levofloxacin in the rabbit model of proarrhythmia J Toxicol Sci 29 2004 63 71
54. Y. Ukai, A. Yamazaki, C. Kurosaka, T. Ishima, Y. Yoshikuni, and K. Kimura Convulsant effects of NM441, e prodrug type antibacterial agent of the quinolone class Jpn J Chemother 44 1996 102 112